156 related articles for article (PubMed ID: 28408177)
1. Effectiveness of natriuretic peptide-guided treatment of chronic heart failure. A meta-analysis.
Gamiño-Arroyo AE; Prado-Galbarro FJ; García-Pérez S; Sánchez-Piedra C
Arch Cardiol Mex; 2018; 88(3):171-177. PubMed ID: 28408177
[TBL] [Abstract][Full Text] [Related]
2. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.
Savarese G; Trimarco B; Dellegrottaglie S; Prastaro M; Gambardella F; Rengo G; Leosco D; Perrone-Filardi P
PLoS One; 2013; 8(3):e58287. PubMed ID: 23472172
[TBL] [Abstract][Full Text] [Related]
3. Natriuretic peptide-guided treatment for heart failure: a systematic review and meta-analysis.
McLellan J; Bankhead CR; Oke JL; Hobbs FDR; Taylor CJ; Perera R
BMJ Evid Based Med; 2020 Feb; 25(1):33-37. PubMed ID: 31326896
[TBL] [Abstract][Full Text] [Related]
4. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.
Savarese G; Musella F; D'Amore C; Vassallo E; Losco T; Gambardella F; Cecere M; Petraglia L; Pagano G; Fimiani L; Rengo G; Leosco D; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2014 Apr; 2(2):148-58. PubMed ID: 24720923
[TBL] [Abstract][Full Text] [Related]
5. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis.
Khan MS; Siddiqi TJ; Usman MS; Sreenivasan J; Fugar S; Riaz H; Murad MH; Mookadam F; Figueredo VM
Int J Cardiol; 2018 Jul; 263():80-87. PubMed ID: 29685696
[TBL] [Abstract][Full Text] [Related]
6. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
[TBL] [Abstract][Full Text] [Related]
7. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
De Vecchis R; Esposito C; Di Biase G; Ariano C; Giasi A; Cioppa C
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):122-34. PubMed ID: 24522083
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
9. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis.
Troughton RW; Frampton CM; Brunner-La Rocca HP; Pfisterer M; Eurlings LW; Erntell H; Persson H; O'Connor CM; Moertl D; Karlström P; Dahlström U; Gaggin HK; Januzzi JL; Berger R; Richards AM; Pinto YM; Nicholls MG
Eur Heart J; 2014 Jun; 35(23):1559-67. PubMed ID: 24603309
[TBL] [Abstract][Full Text] [Related]
10. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials.
Li P; Luo Y; Chen YM
Heart Lung Circ; 2013 Oct; 22(10):852-60. PubMed ID: 23602555
[TBL] [Abstract][Full Text] [Related]
11. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
[TBL] [Abstract][Full Text] [Related]
12. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.
Vaduganathan M; Claggett B; Packer M; McMurray JJV; Rouleau JL; Zile MR; Swedberg K; Solomon SD
JACC Heart Fail; 2018 Jul; 6(7):564-569. PubMed ID: 29501807
[TBL] [Abstract][Full Text] [Related]
13. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
[TBL] [Abstract][Full Text] [Related]
14. Using biomarkers to guide heart failure management.
Chang KW; Fox S; Mojaver S; Maisel AS
Expert Rev Cardiovasc Ther; 2017 Oct; 15(10):729-741. PubMed ID: 28830266
[TBL] [Abstract][Full Text] [Related]
15. Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot?
Logan JK; Mentz RJ
Curr Heart Fail Rep; 2019 Dec; 16(6):250-256. PubMed ID: 31741230
[TBL] [Abstract][Full Text] [Related]
16. Natriuretic peptide guided heart failure management.
Mohammed AA; Januzzi JL
Curr Clin Pharmacol; 2009 May; 4(2):87-94. PubMed ID: 19442073
[TBL] [Abstract][Full Text] [Related]
17. Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials.
Xin W; Lin Z; Mi S
Heart Fail Rev; 2015 Jan; 20(1):69-80. PubMed ID: 24888383
[TBL] [Abstract][Full Text] [Related]
18. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.
Porapakkham P; Porapakkham P; Zimmet H; Billah B; Krum H
Arch Intern Med; 2010 Mar; 170(6):507-14. PubMed ID: 20308637
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
20. Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.
Wessler BS; Kramer DG; Kelly JL; Trikalinos TA; Kent DM; Konstam MA; Udelson JE
Circ Heart Fail; 2011 Sep; 4(5):578-88. PubMed ID: 21705485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
